Argenx To Discontinue UplighTED Studies In Thyroid Eye Disease Due To Futility

Argenx said it is discontinuing its Phase 3 UplighTED studies of Efgartigimod PH20 SC in adults with moderate-to-severe thyroid eye disease after an Independent Data Monitoring Committee recommended stopping for futility following an interim review of 24‑week unblinded data; the stock fell more than 6% in premarket trading. The company will close and lock the database, undertake a comprehensive analysis to understand the outcomes and guide future TED research, and plans to present findings at an upcoming medical meeting. While the decision represents a setback for Argenx’s expansion into TED, its core VYVGART franchise remains strong—Q3 2025 VYVGART net sales were $1.13 billion versus $0.6 billion a year earlier—potentially mitigating near-term financial impact as the firm reassesses its pipeline strategy.

Analysis

Argenx announced discontinuation of its Phase 3 UplighTED studies of Efgartigimod PH20 SC (VYVGART Hytrulo) for moderate-to-severe thyroid eye disease after an Independent Data Monitoring Committee recommended stopping for futility following an interim review of 24-week unblinded data; the stock fell more than 6% in premarket trading and had closed Friday at $877.94, down 1.30%. The IDMC-led futility decision followed a pre-specified interim analysis and the company says it will close and lock the database and perform a comprehensive analysis, with findings to be presented at an upcoming medical meeting; Argenx’s chief medical officer emphasized the analysis was planned and intended to responsibly assess trial viability.

Stopping UplighTED removes a potential label expansion into a condition affecting roughly 19 per 100,000 U.S. patients and represents a material pipeline setback for the TED indication given the drug’s differentiated immunologic mechanism versus steroids or surgery. The company already markets VYVGART for gMG and related indications, and the firm’s commercial franchise remains strong with VYVGART net sales of $1.13 billion in Q3 2025 versus $0.6 billion a year earlier, which should mitigate short-term financial impact.

Key near-term issues for investors are earnings and guidance sensitivity to lost TED upside, potential R&D reprioritization or write-downs following the full data review, and event-driven volatility ahead of the company’s detailed analysis and medical presentation.

Key Decisions for Investors

• Wait for Argenx’s comprehensive data review and medical meeting presentation before increasing exposure to ARGX, as the IDMC futility finding materially increases clinical risk
• If your thesis rests on near-term cash generation, maintain exposure to benefit from the strong VYVGART commercial performance (Q3 2025 sales $1.13B versus $0.6B year-ago), but reprice the stock for reduced pipeline optionality
• Consider short-duration hedges or position size reductions to manage event-driven volatility and monitor any changes to R&D guidance or capital allocation that could follow the halted trials